Recombinant human tyrosyl-tRNA synthetase, a novel thrombopoietic agent.

Abstract

Chemo- and radiotherapy induced thrombocytopenia present significant limitations for tumor therapy. In this study, we examined the therapeutic effect of recombinant human tyrosyl-tRNA synthetase (rhTyrRS) against development of thrombocytopenia in cyclophosphamide (CTX) treated mice. Our data indicate that intraperitoneal administration of at least 10 μg/day rhTyrRS for 7 days significantly prevents the decrease in platelets 8 days after CTX injection. The data further demonstrate that rhTyrRS promotes migration and aggregation of megakaryocytes to the bone marrow niche. Real-time PCR and flow cytometry reveal that VCAM-1 is particularly important for the adhesion. Together, these data suggest that rhTyrRS might be a useful therapeutic agent for chemotherapy-induced thrombocytopenia.

• Authors: Zhan Ling, Zhang Yanling, Feng Zhe, Chen Kui, Zhou Xiushi, Yu Min, Mo Wei
• Journal: European journal of pharmacology (Eur J Pharmacol) Vol. 738 Pg. 293-300 (Sep 05 2014) ISSN: 1879-0712 [Electronic] Netherlands
• PMID: 24907514 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2014 Elsevier B.V. All rights reserved.

Chemical References

• Recombinant Proteins
• Cyclophosphamide
• Tyrosine-tRNA Ligase

Topics

• Animals
• Bone Marrow Cells (cytology, pathology)
• Cell Adhesion (drug effects)
• Cell Movement (drug effects)
• Cyclophosphamide (adverse effects)
• Endothelial Cells (drug effects, pathology)
• Female
• Humans
• Male
• Megakaryocytes (drug effects, pathology)
• Mice
• Recombinant Proteins (pharmacology)
• Survival Analysis
• Thrombocytopenia (chemically induced, physiopathology, prevention & control)
• Thrombopoiesis (drug effects)
• Tyrosine-tRNA Ligase (pharmacology)